Skip to content
Open access

The gut microbiome in chemotherapy-induced fatigue: Exploring clinical associations and modulation via fecal microbiota transplantation in female mice.

Aug 2026 · International Immunopharmacology · Vol 188, pp. 117318 · 0 citations · 63 references
Medicine

TL;DR

Findings are consistent with a role for gut microbes in chemotherapy-induced fatigue and suggest that FMT is not universally beneficial, with effects varying by chemotherapy drug.

Abstract

Background

Fatigue is a common and debilitating side effect of chemotherapy, negatively affecting treatment adherence and survival. Chemotherapy alters gut microbiome composition, and accumulating evidence suggests that gut microbes contribute to chemotherapy-induced fatigue. Because the gut microbiome is modifiable through targeted interventions, such as fecal microbiota transplantation (FMT), microbiome modulation has emerged as a potential strategy to mitigate treatment-related toxicities. To understand the impact of FMT interventions across the gut-brain axis, studying rodent chemotherapy models that simultaneously capture behavioral side effects and gastrointestinal pathology is warranted.

Methods

Patient-reported fatigue and diarrhea were assessed in breast cancer patients before and during chemotherapy (n = 67). In parallel, mice were treated with chemotherapy (5-fluorouracil [5-FU] or paclitaxel) with or without FMT derived from pre-chemotherapy fecal material. Outcomes included fatigue (in-cage locomotion and voluntary wheel running), gut microbiome composition (16S rRNA sequencing), intestinal and brain gene/protein expression (RT-qPCR, single-cell RNA sequencing, and/or multiplex electrochemiluminescence assay), and circulating inflammatory markers.

Results

In patients, increased fatigue during chemotherapy was associated with worse diarrhea and shifts in gut microbiome composition. In mice receiving 5-FU, FMT produced mild-to-moderate benefits, most notably preserving body mass, with milder and transient benefits for fatigue. FMT partially normalized gut bacterial taxa, reduced 5-FU-induced colonic Il1b expression, and prevented chemotherapy-related increases in brain Aqp4. FMT did not attenuate other inflammatory effects induced by 5-FU or paclitaxel.

Conclusion

These findings are consistent with a role for gut microbes in chemotherapy-induced fatigue and suggest that FMT is not universally beneficial, with effects varying by chemotherapy drug.

Read PDF

Similar papers

Review Oct 2026

Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review

TCM represents a promising microbiota-targeted strategy for mitigating chemotherapy-induced toxicities in gastric cancer through gut microbiota regulation, and future studies should focus on STING signaling and the gut–brain axis to advance evidence-based integrative oncology.

Jia-Lin Li, Fa-Xiang Ji · 0 citations
Open access Sep 2026

Microbiome-based probiotic intervention to reduce chemotherapy-induced gastrointestinal toxicity

Introduction Chemotherapy is one of the primary treatment options for cancer; however, its gastrointestinal toxicity and disruption of gut microbial homeostasis can adversely affect patient health and treatment outcomes. This study investigated chemotherapy-induced alterations in the gut microbiome and evaluated the ef...

Hao-Yu Li, Chun-Guang Hou, Yan Pan · 0 citations
Review Open access Jul 2026

Unraveling the bidirectional interplay of the gut microbiota with chemotherapy and radiotherapy in colorectal cancer: from pathogenesis to probiotic interventions.

Colorectal cancer remains a leading cause of cancer-related mortality worldwide. While chemotherapy and radiotherapy serve as a cornerstone of treatment, their clinical efficacy is frequently compromised by therapeutic resistance and gastrointestinal toxicity. Accumulating evidence indicates that the gut microbiota is...

Ke Huang, Geng-Fan Liang, Lan-Fang Jiang et al. · 0 citations
Review Oct 2026

Cancer and the microbiome: from association to intervention.

Current evidence linking the intestinal microbiome to anticancer therapy outcomes is synthesised, strategies and challenges for therapeutic modulation of the microbiome are evaluated, and emerging insights into the mycobiome are introduced.

A. Moradi, R. Winayak, S. Pal · 0 citations
Review Open access Oct 2026

Gut microbiota dysbiosis in pediatric acute lymphoblastic leukemia: clinical consequences, mechanistic insights, and microbiota-targeted interventions

Gut microbiota dysbiosis has emerged as a key feature in pediatric acute lymphoblastic leukemia (ALL), driven by chemotherapy, antibiotic exposure, and treatment-related nutritional impairment. Increasing evidence indicates that disruption of microbial diversity and depletion of short-chain fatty acid–producing bacteri...

Ke Chen, Qing-Qing Li, Y. Xing et al. · 0 citations
Review Open access Sep 2026

Comparative Effects of Microbiota-Modifying Interventions for Gastrointestinal Disorders in Adults with Colorectal Cancer: A Systematic Review and Network Meta-Analysis.

OBJECTIVES Chemotherapy for colorectal cancer (CRC) frequently causes gastrointestinal (GI) toxicities, which may affect treatment adherence and quality of life. These toxicities have been partially linked to chemotherapy-induced alterations in the gut microbiota. This study aimed to compare the effects of microbiota-m...

S. Belloni, A. Magon, Valentina La Bella et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.